ArriVent BioPharma, Inc. Common Stock
AVBPArriVent BioPharma, Inc. (AVBP) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for cancer and autoimmune diseases. The company leverages cutting-edge research to develop targeted treatments aimed at addressing unmet medical needs, with a particular emphasis on immuno-oncology and immunology.
Company News
ArriVent BioPharma announced the first patient dosing in the Phase 3 ALPACCA pivotal trial evaluating firmonertinib for first-line treatment of EGFR PACC mutant NSCLC. The trial compares firmonertinib 240 mg once daily against osimertinib or afatinib, with primary endpoints of overall response rate and progression-free survival. The company estim...
Emerging immunotherapy technologies are transforming treatment for gastrointestinal cancers, with companies developing novel combination strategies to activate immune responses in historically resistant tumors. The global cancer immunotherapy market is projected to reach $443.17 billion by 2030.
ArriVent BioPharma reported a wider net loss in Q2 2025, with increased R&D expenses driven by clinical pipeline expansion and a strategic partnership. The company continues developing firmonertinib for non-small cell lung cancer and initiated a new antibody-drug conjugate program.
